According to Bloomberg, a top Cigna executive said it will prevent patients from paying the full list price for drugs, or more than their employer has contributed.

TD Cowen analyst Ryan Langston maintained a Buy rating on Cigna (CI – Research Report) today and set a price target of $391.00. The company’s ...

Large-scale attacks on health providers expose the data of millions of Americans each year. Consumers must remain vigilant, ...

After UnitedHealthcare CEO Brian Thompson was shot to death in December, law enforcement records show a burst of police ...

Cigna's Evernorth Health Services said on Wednesday its actions will enhance transparency about the company's negotiations.

It’s the latest step from pharmacy benefit managers to respond to relentless criticism from politicians and regulators over ...

CVS Health (NYSE:CVS), Humana (NYSE:HUM), Molina Healthcare (NYSE:MOH), and UnitedHealth Group (NYSE:UNH) saw an upswing ...

Discover how the three largest pharmacy benefit managers are rejecting biosimilars from their formularies, except for their own private-label drugs.

The number of primary care physicians affiliated with hospitals or health systems has spiked in recent years, raising ...

The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

Insurer-pharmacy benefit manager (PBM) firms control most of the Medicare Part D market, steering patients to their ...